The effect of etoposide and camptothecin, two topoisomerase inhibitors directed against topoisomerases II and I, respectively, was evaluated on human peripheral blood lymphocytes. Etoposide and camptothecin induced apoptosis of mitogen-activated but not resting CD4 + and CD8 + T lymphocytes. Cell sensitivity to these agents required G 1 to S-phase transition of the cell cycle. Conversely, daunorubicin, an intercalating agent and topoisomerase II inhibitor, induced apoptosis of both resting and activated lymphocytes. Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists. Drug-induced cell death was also not inhibited by p55 TNFR-Ig fusion protein. Activation of the caspases cascade was suggested by the partial inhibitory effect of the tripeptide zVAD-fmk and documented by activation of caspase 3. Finally etoposide and camptothecin induced a rapid production of ceramide in activated but not resting peripheral blood lymphocytes, suggesting that ceramide might initiate the signaling apoptotic cascade in sensitive cells. Cell Death and Differentiation (2000) 7, 197 ± 206. 
Introduction
Topoisomerases are enzymes that modulate superhelicoõ Èdal density of DNA and act by introducing single (type I) or double (type II) DNA breaks. These enzymes are involved in DNA repair, replication, transcription, and chromosome segregation during mitosis. The topopoisomerase inhibitors CPT and ETO, which inhibit topoisomerase I and II, respectively, stabilize the DNA-single or -double breaks. 1, 2 The effect of these two drugs has been widely studied on cell lines stemmed from solid tumors (e.g. osteoblastoma, 3 hepatoblastoma, 4 colon carcinoma 5 neuroblastoma 6 or glioma 7 ), or hematopoietic cell lines such as promyelocytic, 8 monocytic 9 or lymphoid (CEM 10 and Jurkat 11, 12 ) leukemia cell lines. Topoisomerase inhibitors can induce either inhibition of proliferation or apoptosis, depending on the cell line tested. CPT derivatives are clinically active against human cancers, such as small cell lung cancer, colon or ovarian carcinoma, whereas ETO is used in various leukemias. 13, 14 The apoptotic signaling pathways initiated by chemotherapeutic agents have been recently investigated and evidence for the involvement of the CD95/CD95-L pathway in drug-induced apoptosis has been reported. Indeed doxorubicin increased CD95-L mRNA expression and induced apoptosis in CEM, Jurkat or neuroblastoma cells. In these cells, cell death was inhibited by blocking F(ab') 2 anti-CD95. 6, 15 Similar results were showed by Mu È ller et al 4 in hepatoma cells treated by bleomycin or methotrexate, and using the antagonist Fas-Fc molecule Kasibhatla et al 12 showed that the chimeric protein partially blocked cell death induced by teniposide in Jurkat cells or by ETO in the murine T cell hybridoma 2B4. Moreover a cross-resistance toward doxorubicin and agonistic CD95 mAb was also demonstrated in human myeloma cell line RPMI 8226 10 or in Jurkat 15 and CEM cell lines.
lymphocytes have deserved little investigation so far. Administration of these agents could lead to a modulation of T cell response toward tumor cells with immunosuppressive side-effects. A better knowledge of their action on peripheral lymphocytes may lead to the design of new molecules or new regimens in order to improve the selectivity of tumoricidal versus immunosuppressive effects. In the present study we addressed the capacity of ETO and CPT to induce apoptosis of peripheral blood lymphocytes. We asked whether sensitivity of PBL to ETO and CPT depends on mitogenic activation, and we investigated processes involved in the apoptotic signaling.
Results
Etoposide and Camptothecin induce apoptosis of activated but not resting peripheral blood lymphocytes
Since ETO and CPT were previously reported to inhibit the proliferation of T cell lines such as Jurkat, CEM, L1210 and MOLT-4, 1,2,32 we have investigated whether ETO and CPT would also affect proliferation of PBL activated by different mitogens. As shown in Figure 1 , when PBL were activated for 3 days in the presence of PHA and then incubated with ETO and CPT, a dose dependent inhibition of proliferation was observed. Maximal inhibitory effect was observed with 2 and 0.1 mM of ETO and CPT, respectively. Since inhibition of proliferation could reflect induction of cell death, we measured apoptosis induced by these drugs. Resting PBL, or 3 day-PHA blasts, were incubated for 24 h with ETO and CPT at concentrations ranging from 2 nM ± 10 mM and 1 nM ± 10 mM, respectively and the percentage of apoptotic cells was determined by fluorescence microscopy after Hoechst 33342 staining. The percentage of apoptotic cells among PHA-activated PBL increased in a dose-dependent manner in the presence of ETO and CPT but no apoptosis was seen in non-activated cells. Under the same conditions another chemotherapeutic agent, DNR which acts both as DNA intercalating agent and topoisomerase II inhibitor, induced apoptosis of both resting and activated PBL in the same range of concentrations (2 nM ± 2 mM) ( Figure 1 ). Apoptosis of PHA-activated but not resting PBL with ETO or CPT was confirmed by the decrease of mitochondrial transmembrane potential (DCm), measured by staining with DiOC 6 (3) and by the externalization of phosphatidylserine measured by annexin V binding (data not shown). Activation-dependent apoptosis was also observed when PBL were stimulated with Con A, SEB, PMA plus ionomycin, immobilized or soluble OKT3 (Table  1) . Incubation of 3 day-PHA blasts with ETO or CPT at 2 mM and 1 mM respectively (concentrations which induced 50% of apoptosis), indicated that the number of apoptotic cells increased rapidly to reach a maximum after 15 h of exposure to the drugs (Figure 2 ). Double fluorescence analysis demonstrated that both CD4 + /AnnexinV + and CD8 + /AnnexinV + populations increased after 20 h-incubation with ETO or CPT (Figure 3 ).
Sensitivity to Etoposide and Camptothecininduced apoptosis requires G1 to S-phase transition
Because ETO and CPT are topoisomerase inhibitors and since only activated PBL were susceptible to apoptosis, we hypothesized that cells might need to be cycling in order to be sensitive to ETO and CPT-mediated apoptosis. In order to test this hypothesis we used aphidicolin, a DNA synthesis inhibitor that accumulates cells in late G1, or the immunosuppressive agents CsA, FK506 and RPM, which interfere with IL-2 gene transcription (CsA and FK506 33 ) or IL-2 signaling (RPM 34 ), and subsequently inhibit proliferative response of PHA-activated PBL by blocking the progression from G1 to S-phase of the cell cycle. Addition of aphidicolin (125 ng/ml), CsA (250 ng/ml), FK506 (10 nM) or RPM (60 nM) during the 3-day activation period with PHA did not inhibit CD25 expression but reduced cellular proliferation by 60% and markedly reduced ETO-and CPT-mediated apoptosis ( Figure 4A ). In contrast addition of either CsA, FK506 or RPM to activated PBL just 4 h before treatment with ETO or CPT did not decrease the percentage of apoptotic cells ( Figure 4B ). Finally addition of IL-2 to lymphocytes culture in presence of PHA plus CsA restores cell proliferation and sensitivity to topoisomerase inhibitors (data not shown).
Etoposide and Camptothecin-induced apoptosis does not require CD95/CD95-L interaction
In agreement with the above data we observed that maximal susceptibility of activated PBL to ETO and CPT was achieved after 3 days of activation and declined thereafter, following [ 3 H]TdR uptake kinetics ( Figure 5A ). Susceptibility to CD95-mediated cell death followed different kinetic, increasing progressively up to day 5 ( Figure 5A ) as previously reported. 35 ± 37 To further investigate the role of CD95/CD95-L interaction in ETO-and CPT-induced apoptosis, we assessed CD95-L mRNA expression by RT ± PCR. Treatment of activated PBL with ETO or CPT at 2 and 1 mM, respectively, significantly increased CD95-L mRNA expression only after 12 h. Under the same conditions incubation of cells in the presence of PMA plus ionomycin showed an early peak at 6 h ( Figure 6 ).
We next investigated whether ETO and CPT-induced apoptosis required CD95/CD95-L interaction. To this end, 3 day-PHA-activated PBL were preincubated for 1 h with blocking Fas-Fc fusion protein before addition of either ETO, CPT or CD95 agonistic mAb 7C11. Only apoptosis induced by the addition of 7C11 was blocked by the Fas-Fc fusion protein whereas ETO-and CPT-mediated apoptosis was not ( Figure 5B ). Further analysis on kinetics of ETO-or CPT-induced apoptosis in presence of FasFc showed that apoptosis was not delayed or diminished at any time of the kinetic ( Figure 5C ). Similar results were obtained with ZB4 or BD29, two antagonistic anti-CD95 mAbs used at 2 and 
of three independent experiments
Cell Death and Differentiation Drug-induced apoptosis of activated peripheral lymphocytes C Ferraro et al 5 mg/ml respectively (data not shown). Finally because 3 day-PHA-activated PBL are not fully sensitive to CD95-mediated apoptosis we also tested whether CD95-dependent mechanisms may contribute to ETO-and CPT- Figure 5A preincubation of activated PBL with the CD95 antagonist ZB4 never affected ETO-or CPTmediated apoptosis whereas it markedly reduced CD95-induced apoptosis. Altogether these data indicate that despite the induction of CD95-L mRNA expression under ETO and CPT treatment, apoptosis of activated PBL induced by the two drugs does not require CD95/CD95L interaction. We also tested whether ETO-and CPTmediated apoptosis required TNFa/TNFR interaction. Preincubation of activated PBL with soluble p55 TNFR-Ig did not affect ETO-and CPT-induced apoptosis whereas in the same conditions it completely inhibited apoptosis induced by TNFa ( Figure 5B ).
Etoposide and Camptothecin-induced apoptosis requires caspase activation
To further investigate ETO and CPT death signaling pathway in activated PBL, we tested whether activation of caspases was required. When 3-day-activated PBL were preincubated for 90 min in presence of zVAD-fmk at concentrations ranging from 1 ± 100 mM before addition of ETO, CPT or 7C11 mAb, we observed a very efficient inhibition of CD95-mediated cell death at 10, 50 and 100 mM. Apoptosis induced by both ETO and CPT was only partially inhibited by zVAD-fmk, with 31 ± 51% inhibition at 50 mM and 50 ± 56% inhibition at 100 mM ( Figure 7) . In order to clearly demonstrate caspase activation during apoptosis induced by ETO and CPT we tested the cleavage of the caspase 3 proenzyme as well as its substrate PARP. Caspase 3 underwent proteolytic processing from the 32 kDa proform during ETO, CPT or anti-CD95 treatment of PHA-activated PBL. Decrease of the procaspase 3 band was detectable 6 h after addition of ETO or CPT (Figure 8) . PARP was present as a full length protein of 116 kDa in untreated cells. Processing of PARP into its 85 kDa signature fragment was induced by CPT and ETO treatment after 2 or 6 h respectively ( Figure 8 ) and by anti-CD95 treatment as previously reported. 37 Induction of procaspase 3 and PARP cleavage by CPT and ETO but also by the anti-CD95 agonistic mAb was restricted to PHA-blasts, which correlates with the observation that activated but not resting PBL are susceptible to ETO-CPT-and anti-CD95-induced apoptosis. The inhibitory peptide zVAD-fmk at 100 mM, which inhibited drug-induced apoptosis by about 50% (Figure 7 ) completely inhibited procaspase 3 and PARP cleavage (Figure 8 ).
Etoposide and Camptothecin induce ceramide production in activated PBL
Among recognized bioactive molecules in signal transduction, ceramide is a potent mediator of apoptosis induced by diverse chemotherapeutic agents in lymphoid and monocytic cell lines. 25, 27, 28, 30, 39 We investigated whether CPT and ETO would induce ceramide production in PBL. Lipids were extracted from resting or 3-day-activated PBL treated with CPT or ETO, and endogenous production of ceramide was measured by a diacylglycerol kinase assay. As shown in Figure 9 we observed that both CPT and ETO induced a rapid increase in the level of ceramide in activated but not in resting PBL. Ceramide production after CPT treament was maximal after 60 min and decreased rapidly thereafter to reach the basal level after 2 h. When cells were treated with ETO, maximal production was observed at 30 min ( Figure 9 ).
Discussion
Previous studies have provided some evidence that apoptosis of leukemia cell lines, 12, 15 hepatoma cells 4 as well as T cell hybridomas 12 induced by chemotherapeutic agents such as CPT and ETO may proceed via a CD95/CD95-L dependent pathway in a manner analogous to activation-induced cell death. When used in cancer chemotherapy these agents may develop their cytotoxicity towards malignant cells as well as normal lymphocytes leading to deletion of activated tumorinfiltrating lymphocytes. The present study was therefore focussed on the effects of these compounds on resting and mitogen-activated PBL as a first simple assessment of drug cytotoxicity. We observed that CPT and ETO can induce apoptosis of both CD4 + or CD8 + activated but not resting PBL. CPT and ETO were previously described as S and G 2 /M specific agents. 5,40 ± 42 However some reports demonstrated that CPT can also induce apoptosis in a cell-cycle independent fashion. 7, 43 Here we observed that induction of apoptosis by ETO and CPT is restricted to mitogen-activated PBL with a maximal percentage of apoptotic cells observed at 3 days of activation. Conversely, DNR which acts both as an intercalating agent and topoisomerase II inhibitor induced apoptosis of both resting and activated T cells. Accumulating cells in late G1 with aphidicolin or blocking G 1 to S-phase transition of the cell cycle by addition of CsA or FK506 which interfere with IL-2 gene transcription 33 or RPM which inhibits IL-2 signaling 34 protected cells from ETO-and CPT-mediated apoptosis, indicating that sensitivity of PBL to ETO and CPT requires G 1 to S-phase transition. Addition of CsA, FK506 or RPM to pre-activated PBL, just 4 h before treatment with either ETO or CPT, did not modify drug-induced apoptosis whereas such treatment almost completely reduced apoptosis induced by PMA associated to ionomycin ( 44 and our data not shown), suggesting that these immunosuppressive agents do not affect the signaling pathway triggered by ETO and CPT but rather prevent acquisition of susceptibility to ETO-and CPT-mediated cell death. Involvement of CD95/CD95-L interaction in drug-induced apoptosis remains controversial. 4, 11, 15 In our experiments, three different CD95 antagonists, Fas-Fc fusion protein and two mAb ZB4 and BD29 which all inhibit CD95-L-mediated cell death ( 45 and Vermot-Desroches, unpublished data), did not exhibit any protective effect against ETO-or CPTinduced apoptosis of activated PBL which in the same experiments were shown to be fully sensitive to CD95-mediated apoptosis. Furthermore, using soluble p55 TNF-R Ig, we also eliminated the possibility that ETO and CPT can mediate apoptosis of activated PBL in a TNF-dependent pathway.
Interestingly we observed that the zVAD-fmk inhibitory peptide was about 10 ± 50-fold more efficient in blocking CD95-mediated apoptosis as compared with drug-induced cell death, suggesting that requirement for caspases may be different in the two pathways. In agreement with previous reports in different experimental models 19, 46 our results indicate that ETO-or CPT-induced apoptosis of activated PBL may be in part independent of caspases activation. It was already reported that some death inducers, such anti-CD2 monoclonal antibodies, staurosporine as well as the pro-apoptotic protein Bax 47,48 which induce caspase activation are however not blocked by the broad spectrum inhibitor zVAD. The tripeptide zVAD only prevented DNA fragmentation, a characteristic feature of apoptosis but not alterations in mitochondrial function, cell permeability and finally cell death. Similarly, cell permeable ceramides were also reported to induce cell death in a caspase independent fashion. 49 Generation of ceramides has been already described with various chemotherapeutic agents. 25, 27, 28, 30, 38, 50 Here we report that ETO and CPT increased the generation of ceramide in sensitive (activated) but not in resistant (resting) PBL. Ceramide production was maximal after 30 and 60 min of treatment with ETO or CPT, respectively, corresponding to the earliest signal observed in ETO-and CPT-induced apoptosis. Indeed, generation of ceramide preceded activation of caspase 3 and PARP cleavage that occured 6 h after addition of the drugs. We previously observed that cell permeable ceramides can induce caspase activation, permeability transition and subsequent cell death of both resting and activated PBL. However mitochondrial dysfunc- Figure 8 ETO and CPT induce caspase 3 and PARP cleavage. Freshly purified PBL or 3-day-PHA-activated PBL were treated for the indicated time with ETO (2 mM), CPT (1 mM) or the CD95 agonist mAb 7C11 (1 mg/ml). PHA-activated PBL were also cultured 3 h in the presence of tetrapeptide zVAD-fmk before being treated by ETO (2 mM), CPT (1 mM) or the CD95 agonist mAb 7C11 (1 mg/ml) for 6 h. Cell extracts were processed as described in Materials and Methods, subjected to SDS ± PAGE, transferred to nitrocellulose, and probed with antibodies that recognize procaspase 3 (32 kDa) or PARP (116 kDa) and its signature fragment (85 kDa)
Cell Death and Differentiation Drug-induced apoptosis of activated peripheral lymphocytes C Ferraro et al tion and cell death were still observed in the presence of zVAD-fmk, despite decreased PARP cleavage ( 38 and our unpublished data). So, in our model, the partial inhibition of apoptosis by zVAD-fmk can reflect the capacity of ceramide to alter mitochondrial dysfunction and to promote cell death in a caspase independent manner. The signals generated by DNA alterations that lead to ceramide production are still undefined. Ceramide has been recently demonstrated to be generated as a consequence of p53 activation during actinomycin D treatment of MOLT-4 cells. 30 However ceramide production by activated PBL may not depend on p53 because Strasser et al. 51 reported that g-radiationinduced apoptosis of murine splenocytes was p53-independent. Implication of other regulators of cellular response to DNA damage remains to be investigated.
Despite the demonstration that both CPT and ETO can induce apoptosis in a CD95/CD95-L-independent pathway, we observed a strong induction of CD95-L mRNA expression by these two drugs. However ETO-and CPTstimulated CD95-L mRNA expression showed a peak at 12 h which corresponds to delayed kinetics as compared with (i) that of CD95-L mRNA expression during activationinduced cell death of PBL triggered by PMA associated to ionomycin stimulation, and with (ii) the rapid kinetics of apoptosis ( Figure 2 ) and caspase 3 activation that are observed after 2 and 6 h of exposure to CPT and ETO, respectively. Altogether these data suggest that the increase in CD95-L mRNA expression might not be relevant to ETO-and CPT-mediated apoptosis in PBL, but rather reflect a secondary event of drug signaling in this cellular model. In agreement with this hypothesis, we observed that the addition of zVAD-fmk which partially inhibited apoptosis of PBL, did not decrease but rather sligthly increased CD95-L mRNA level in both ETO-and CPT-treated cells (data not shown) suggesting that upregulation of CD95-L mRNA is not directly linked to the capacity of these two drugs to induce cell death.
Finally our results suggest that the T cell dependent immune responses that develop at the time of administration of these drugs may be impaired as a consequence of peripheral T cell clonal deletion, although such side effect remains limited to T cells that undergo mitogenic activation.
Materials and Methods
Cell preparation and culture PBL were collected from healthy donors in the presence of sodium citrate. Blood was defibrinated, then mononuclear cells were isolated by centrifugation on a layer of histopaque 1 (Dutcher, Brumath, France). Those cell suspensions referred to as PBL contained 1.8+0.4% monocytes and 4 ± 11% B lymphocytes as defined by expression of CD14 and CD20, respectively. PBL were resuspended in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 10% fetal calf serum, 2 mM L-glutamine, and antibiotics (penicillin 100 U/ ml, Streptomycin 100 mg/ml). Cells (1610 6 /ml) were incubated in the presence of different mitogens. Cultures were maintained in a humid atmosphere containing 5% CO 2 for 72 h. For proliferation assay cells were pulsed during the indicated time with (methyl- 
Antibodies and reagents
A stock solution of ETO (kindly provided by Novartis, Basel, Switzerland) was prepared in ethanol at a concentration of 2 mM. CPT (Sigma, St Louis, MO, USA) was dissolved in DMSO at 20 mM. DNR was purchased from ICN biochemicals (Costa Mesa, CA, USA) and dissolved in distilled water. Different mitogens were used: PHA, PMA, ionomycin, SEB, Con A (Sigma), and the CD3 mAb OKT3 (Cilag Laboratories, Levallois Perret, France). CsA was kindly supplied by Novartis Corporation. FK506 and RPM were kindly supplied by Dr. Altman (La Jolla, CA, USA). Aphidicolin was purchased from Sigma. Fluorescein-isothiocyanate (FITC)-conjugated CD25 mAb or phycoerythrin (PE)-conjugated CD4 or CD8 mAbs were obtained from Becton Dickinson (Pont de claix, France). Purified anti-Fas mAb agonist (IgM, clone 7C11) and antagonist (IgG1, clone ZB4) were purchased from Immunotech (Marseille, France), the anti-Fas mAb antagonist BD29 was kindly provided by C. Vermot-Desroches (Diaclone, Besanc Ë on, France). Fas-Fc fusion protein and TNF-R p55 Ig fusion protein were kindly provided by Dr. D. Green (La Jolla, CA, USA) and Dr. H. Waldman (Oxford, UK), respectively. TNFa was obtained from R&D systems (Oxon, UK). The caspase inhibitory peptide zVAD-fmk was from Bachem (Voisins le Bretonneux, France).
Measurement of apoptosis
After 3 days of culture, PHA-activated PBL were harvested. Dead cells were removed by centrifugation on a layer of histopaque (Sigma) and washed in Hank's balanced salt solution. Viable cells (10 6 /ml) were incubated in 96-well microplates with various drugs. After 20 h of incubation, cell death was evaluated by fluorescence microscopy after staining with Hoechst 33342 (Sigma) at 10 mg/ml following previously described methods. 52 Nuclear fragmentation and/or marked condensation of the chromatin with reduction of nuclear size were considered as typical features of apoptotic cells. Based on these measurements, results were expressed as percentage of specific apoptosis according to the following formula: % specific apoptosis test À control Â 100 100 À control
Annexin V binding
Exposure of surface phosphadidylserine was quantified by surface annexinV staining as described previously. 53 Cells were resuspended in binding buffer and incubated with FITC-conjugated annexin V (Bender MedSystems, Austria) for 5 min. Cells were analyzed by flow cytometry (Becton Dickinson; l. Ex. Max., 488 nM; l. Em. Max., 525 nm) with the LYSYS II software.
RNA isolation, reverse transcription, PCR ampli®cation and quanti®cation
Total cellular RNA was isolated from 3 day-PHA activated PBL subsequently cultured for 6 or 12 h in presence or absence of ETO (2 mM), CPT (1 mM) or PMA (10 ng/ml) plus ionomycin (0.5 mg/ml). RNA was isolated by the method of Chomczynski and Sacchi. 54 Reverse transcription and PCR was performed as previously described. 55 Determination of procaspase 3 and poly(ADP-ribose) polymerase (PARP) cleavage
Cleavage of PARP and procaspase 3 was determined by Western blotting. Cells (1610 6 ) were washed twice in phosphate buffered saline, pelleted, and lysed in 100 ml of lysis buffer containing 62.5 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 2% b2-mercaptoethanol. After 10 min on ice, 20 ml of 56 sample buffer were added, and samples were heated for 5 min at 958C. Thirty ml of the lysate were subjected to 7.5% (PARP) or 15% (procaspase 3) SDS-polyacrylamide gel electrophoresis gel and transferred to nitrocellulose membrane. Blots were probed using anti-PARP mAb C-2-10 (Biomol, TEBU, Le Perray en Yvelines, France) or anti-caspase 3 mAb (Transduction Laboratories, Lexington, KY, USA). Bound antibodies were detected with rabbit anti-mouse peroxidase-conjugate (Biorad, Ivry sur Seine, France). An enhanced chemioluminescence system (Amersham), was used for detection.
Ceramide measurement
Ceramide was quantified by the diacyglycerol kinase assay as 32 P incorporated upon phosphorylation of ceramide to ceramide-1-phosphate by diacylglycerol (DG) kinase from Eschericchia coli (Biomol, Plymouth Meeting, PA, USA) as previously described. 50 Briefly, after 3 days of culture, 2610 7 PBL were starved for 2 h in RPMI containing 2% BSA and then treated with ETO, CPT or a CD95 agonistic mAb (7C11) for indicated time. Ceramide-1-phosphate was resolved by TLC using CHCl 3 
